Literature DB >> 2244692

Cardiogenic hepatorenal syndrome.

J E Naschitz1, D Yeshurun, J Shahar.   

Abstract

A variant of hepatorenal syndrome occurring in patients with chronic congestive heart failure following an episode of cardiogenic pulmonary edema, and in the absence of hypotension, is described. This was observed in 13 patients during an eleven-year period. The clinical picture is characterized by hepatic injury and functional renal impairment. Increase of serum glutamic oxaloacetic transaminase levels as high as 2100 IU; prolongation of prothrombin time; elevation of serum bilirubin, creatinine, blood urea nitrogen, and potassium levels; decrease in urinary sodium excretion; and a normal urinary sediment are the salient laboratory abnormalities of this entity. Treated with conventional medication, the patients' course was fatal in 4 cases. When the splanchnic vasodilator dopamine was added to the patients' management, 5 of 9 patients recovered. Cardiogenic hepatorenal syndrome is a severe but potentially reversible complication of heart failure. The apparently beneficial effect of low-dose dopamine needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244692     DOI: 10.1177/000331979004101101

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure.

Authors:  Nimer Assy; Hana Gefen; Sorina Schlesinger; Osamah Hussein
Journal:  Dig Dis Sci       Date:  2007-12       Impact factor: 3.199

Review 2.  Relationship between Heart Disease and Liver Disease: A Two-Way Street.

Authors:  Hamza El Hadi; Angelo Di Vincenzo; Roberto Vettor; Marco Rossato
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

3.  Synthesis, Molecular Docking, and Preclinical Evaluation of a New Succinimide Derivative for Cardioprotective, Hepatoprotective and Lipid-Lowering Effects.

Authors:  Muhammad Imran Qayyum; Sami Ullah; Umer Rashid; Abdul Sadiq; Mater H Mahnashi; Osama M Alshehri; Mohammed M Jalal; Khalid J Alzahrani; Ibrahim F Halawani
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.